Anti-Seizure and Anti-Epileptogenic Effects of New, Selective mTor Inhibitors

PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 04/10/2020

Pipeline Type

New Drugs in Development

Phase Of Development

Preclinical

Sponsors and Collaborators

PIQUR Therapeutics, Wolfgang Loescher, Epilepsy Foundation (EF)

Mechanism of Action

mTOr

Mechanism Description

mTOR inhibitors

Populations Tested In

Tuberous Sclorosis rodent models

Special FDA Designation

Nonprofit or Government Support

Nonprofit

Nonprofit or Government Support Description

Epilepsy Foundation - NTCG 2017

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A

Location of Clinical Trials

N/A

Clinical Trial link

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.